Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome

This study shows that adalimumab is an effective treatment in patients with UC. If used as a second anti-TNF, previous achievement of remission with the first anti-TNF predicts response, and failure to achieve response at week 12 predicts colectomy.